Open Journal Systems

Clinical Efficacy of Apatinib Combined with Gemcitabine on the Third Line or above in Patients with Advanced Lung Cancer and Its Effect on Serum Tumor Marker Levels

X. Song (Jinzhou Medical University, Jinzhou City, Liaoning Province, China)
S. Li (Jinzhou Medical University, Jinzhou City, Liaoning Province, China)

Abstract


Objective. To analyze the clinical efficacy of apatinib combined with gemcitabine monotherapy for patients with third-line or higher advanced non-small cell lung cancer and its effect on serum tumor markers CA125, CEA, and CYERA21-1. Methods. A retrospective analysis was performed on 62 patients with stage III and IV third-line and above non-small cell lung cancer treated in the hospital from October 2016 to October 2018. Among them, 31 patients received gemcitabine monotherapy as a control group and 31 patients treated with apatinib combined with gemcitabine were used as the observation group, and the objective response rate (ORR), disease control rate (DCR), progression-free survival, overall survival of the two groups were compared and analyzed. Changes of serum tumor marker carbohydrate antigen (CA125), carcinoembryonic antigen (CEA), and cytokeratin fragment 19 (CYFRA21-1) in the two groups were observed before and after treatment. Results. After 8 weeks of treatment, the objective response rate of the observation group was 32.3%, the disease control rate was 80.6%, the objective response rate of the control group was 19.4%, the disease control rate was 58.1%, and the objective response rate and disease control rate of the observation group All were higher than the control group, and the difference was statistically significant ORR (χ2= 4.343, P<0.05), DCR(χ2=0.037, P<0.05); compared with the control group, the median PFS was 5.9 months and 3.3 months (P<0.05), OS was 9.1 months and 5.8 months (P<0.05), mPFS and OS in the observation group were longer than those in the control group, and the differences were statistically significant (P<0.05). Tumors average levels of markers in the observation group and control group were lower than before treatment. The serum tumor markers in patients in the observation group were significantly higher than those in the control group, and the differences were statistically significant (P> 0.05). Conclusion. For patients with advanced non-small cell lung cancer, three-line or more treatment with apatinib combined with gemcitabine compared with gemcitabine single-drug regimen has improved short-term and long-term efficacy, and most of the adverse reactions are tolerable and safe.


Keywords


Apatinib; Gemcitabine; Non-small cell lung cancer; Serum tumor markers; Clinical efficacy

Full Text:

PDF

References


Du Zhenya, Jia Ruhan, Li Wenhui, et al. Molecular characterization and characterization of peroxidase 4 aptamer in early gastric cancer [J]. Chinese Journal of Biochemistry and Molecular Biology,2018,34(10):1065-1072.

WJ Koemans, RT van der,Kaaij H Boot,et al.Cytore ductive surgery and hyperthermic intraperitoneal chemoth erapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, The multicentre randomised controlled trial with Periscope II [J].BMC Cancer,2019,19(1):1-8.

Wang Su, Jiang Junyan, Zheng Zidan. Clinical significance of pepsinogen in the differential diagnosis of chronic atrophic gastritis and early gastric cancer [J]. Hebei Medical Journal,2017,39(19):2930-2932,3935.

Fan Ning-fang, Cui Ya-li, Jin Jian-hua. The value of serum homocysteine and related tumor markers in the differential diagnosis of early and advanced gastric cancer [J]. Chinese Journal of Pharmacology and Clinics,2019,19(7):1160-1162.

T Yoshizaki, D Obata, Y Aoki, et al.Endoscopic submu cosal dissection for early gastric cancer on the lesser curvature in upper third of the stomach is a risk factor for postoperative delayed gastric emptying [J].Surgical Endos Copy, 2018, 32 (8) : 3622-3629.

Shu Meiling, Wang Qiang, Long Xiaoqi. Clinical significance of endoscopic staining with acetic acid-rubine in the diagnosis of early gastric cancer [J]. Journal of Clinical Military Medicine,2019,47(1):41-43,46.

Wang N, Xu XY, Shen H, et al. The value of Nedd9, Ki67, P53 combined detection in early diagnosis and malignant grade assessment of gastric cancer [J]. Journal of Applied Medicine,2017,33(12):1961-1965.

Sun Shanming, Tian Qiang, Wei Xin, et al. Application of narrow band imaging amplification gastroscopy combined with rubin-carmes staining in the diagnosis of early gastric cancer and precancerous lesions [J]. Chinese Journal of Digestive Endoscopy,2017,34(2):134-136.

H Shinohara, Y Kurahashi, S Haruta, et al.Universalization of the operative strategy by systematic mesogastric excision for stomach cancer with that for total mesorectal excision and complete mesocolic excision colorectal counter parts [J]. Gastroenterological Surgery,2018,2(1): 28-36.

Hong Jing, Feng Zhen, Cheng Zhonghua, et al. Clinical significance of narrow band imaging with white light gastroscopy in the diagnosis of atrophic gastritis and early gastric cancer [J]. Journal of Clinical and Experimental Medicine,2018,17(11):1189-1192.

ZHOU Zhenyu, HONG Ming. Clinical significance of gastric window contrast-enhanced ultrasound and high-frequency small probe endoscopic ultrasonography in preoperative T staging of early gastric cancer [J]. Journal of Applied Cancer, 2018,33(12):2023-2025,2029.

Pan Y, Zhang YJ, Zhang Y, et al. The value of CBI endoscopy in the diagnosis of early gastric cancer [J]. Gastroenterology,2018,23(9):526-529.



DOI: http://dx.doi.org/10.30564/amor.v6i5.284

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 X. Song, S. Li

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.